These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16707477)

  • 1. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
    Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
    Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM
    Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
    Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
    Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
    Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
    Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.
    Ishikawa T; Nakai N; Liu NN; Shiba K; Isozaki K; Matsuda I; Ito T; Fujimoto J; Hatakeyama K; Kanda T; Hirota S
    Lab Invest; 2009 Oct; 89(10):1161-8. PubMed ID: 19636292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
    Rossi F; Ehlers I; Agosti V; Socci ND; Viale A; Sommer G; Yozgat Y; Manova K; Antonescu CR; Besmer P
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12843-8. PubMed ID: 16908864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
    Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
    Bauer S; Yu LK; Demetri GD; Fletcher JA
    Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.